257 related articles for article (PubMed ID: 37532934)
41. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
42. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
Dong P; Kaneuchi M; Watari H; Hamada J; Sudo S; Ju J; Sakuragi N
Mol Cancer; 2011 Aug; 10():99. PubMed ID: 21851624
[TBL] [Abstract][Full Text] [Related]
44. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
45. Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness.
Yan W; Han P; Zhou Z; Tu W; Liao J; Li P; Liu M; Tian D; Fu Y
Dig Dis Sci; 2014 Jun; 59(6):1213-21. PubMed ID: 24442237
[TBL] [Abstract][Full Text] [Related]
46. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
[TBL] [Abstract][Full Text] [Related]
47. Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer.
Wischhusen J; Wilson KE; Delcros JG; Molina-Peña R; Gibert B; Jiang S; Ngo J; Goldschneider D; Mehlen P; Willmann JK; Padilla F
Theranostics; 2018; 8(18):5126-5142. PubMed ID: 30429890
[TBL] [Abstract][Full Text] [Related]
48. A novel epithelial-mesenchymal transition-related lncRNA signature predicts prognosis and immune status in endometrioid endometrial cancer.
Jin Y; Qiu Y; Li Y; Jiang Z; Hu S; Dai H
Medicine (Baltimore); 2023 Jun; 102(26):e34126. PubMed ID: 37390286
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines.
Dong P; Kaneuchi M; Watari H; Sudo S; Sakuragi N
Mol Carcinog; 2014 May; 53(5):349-59. PubMed ID: 24002805
[TBL] [Abstract][Full Text] [Related]
50. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
Ducarouge B; Redavid AR; Victoor C; Chira R; Fonseca A; Hervieu M; Bergé R; Lengrand J; Vieugué P; Neves D; Goddard I; Richaud M; Laval PA; Rama N; Goldschneider D; Paradisi A; Gourdin N; Chabaud S; Treilleux I; Gadot N; Ray-Coquard I; Depil S; Decaudin D; Némati F; Marangoni E; Mery-Lamarche E; Génestie C; Tabone-Eglinger S; Devouassoux-Shisheboran M; Moore KJ; Gibert B; Mehlen P; Bernet A
Cell Death Differ; 2023 Oct; 30(10):2201-2212. PubMed ID: 37633969
[TBL] [Abstract][Full Text] [Related]
51. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
[TBL] [Abstract][Full Text] [Related]
52. Integrating single-cell RNA-seq and spatial transcriptomics reveals MDK-NCL dependent immunosuppressive environment in endometrial carcinoma.
Yu X; Xie L; Ge J; Li H; Zhong S; Liu X
Front Immunol; 2023; 14():1145300. PubMed ID: 37081869
[TBL] [Abstract][Full Text] [Related]
53. Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.
Dong P; Ihira K; Xiong Y; Watari H; Hanley SJ; Yamada T; Hosaka M; Kudo M; Yue J; Sakuragi N
Oncotarget; 2016 Apr; 7(15):20260-70. PubMed ID: 26934121
[TBL] [Abstract][Full Text] [Related]
54. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
55. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
56. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S; Scambia G; Schettino C; Arenare L; Pisano C; Lombardi D; De Giorgi U; Andreetta C; Cinieri S; De Angelis C; Priolo D; Casanova C; Rosati M; Greco F; Zafarana E; Schiavetto I; Mammoliti S; Cecere SC; Salutari V; Scalone S; Farolfi A; Di Napoli M; Lorusso D; Gargiulo P; Califano D; Russo D; Spina A; De Cecio R; Chiodini P; Perrone F;
Lancet Oncol; 2023 Mar; 24(3):286-296. PubMed ID: 37052965
[TBL] [Abstract][Full Text] [Related]
57. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma.
Sato I; Ishibashi M; Tokunaga H; Shigeta S; Sakurada S; Shimada M; Nagase S; Watanabe Y; Yaegashi N
Tohoku J Exp Med; 2020 Aug; 251(4):263-272. PubMed ID: 32727972
[TBL] [Abstract][Full Text] [Related]
59. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
Cowherd S; Miller LD; Melin SA; Akman S; Isom S; Cole J; Pullikuth A; Lawrence JA
Cancer Biol Ther; 2015; 16(5):678-83. PubMed ID: 25928118
[TBL] [Abstract][Full Text] [Related]
60. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
